CRISPR THERAPEUTICS AG
About CRISPR THERAPEUTICS AG
CRISPR Therapeutics AG is a leading gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 gene-editing platform. The company has raised capital from various sources including nearly $89 million in venture funding from Versant Ventures, SR One, New Enterprise Associates, Abingworth and Celgene Ventures, as well as funding from corporate partners Vertex Pharmaceuticals and Bayer AG. It is publicly traded on NASDAQ under the ticker CRSP and has expanded operations from Switzerland to Cambridge, Massachusetts.
- 🔗 CRISPR Therapeutics, Inc. - MassBio
- 🔗 CRISPR Therapeutics Announces Pricing of Public Offering of Common Shares | CRISPR Therapeutics
- 🔗 Crispr Therapeutics (CRSP) | Portfolio | Versant Ventures
- 🔗 Crispr Therapeutics Stock Price Today NASDAQ CRSP - Investing.com Canada
- 🔗 About Crispr Therapeutics AG (CRSP) - Investing.com
Key highlights
- Raised nearly $89 million in venture funding from leading firms including Versant Ventures and SR One.
- Completed $142 million Series B in 2016 leading to NASDAQ listing.
- Maintains strategic collaborations with Vertex Pharmaceuticals and Bayer AG.
- Focuses on CRISPR/Cas9 platform for serious disease treatments with $1.86 billion in cash reserves reported.
Ask StreetZero about CRISPR THERAPEUTICS AG
Put our AI to work on this deal.
Similar companies
Other Public Equity (NASDAQ) deals, ranked by Signal.
Source document & SEC filing
The source SEC filing and the cached document are available to members only. Sign in to view and download them.
Sign in to view the filing Create free account